Georgiamune is a clinical-stage biotechnology company based in Gaithersburg, Md., focused on reprogramming immune signaling pathways to redirect the immune system against cancer and autoimmune diseases. The company announced FDA clearance of an IND for GIM-122, a dual-functioning monoclonal antibody. Georgiamune plans a first-in-human, open-label, phase 1/2 dose-escalation with enrichment and dose-expansion study to assess safety, tolerability, pharmacokinetics/pharmacodynamics and antitumor activity of GIM-122 as a single agent in adults with advanced solid malignancies who have failed checkpoint inhibitors. The company intends to initiate the phase 1/2 clinical trial in the second half of 2023. Led by founder and CEO Dr. Samir Khleif, Georgiamune will continue development of its first-in-class pipeline addressing high unmet needs in cancer and autoimmune diseases. The company recently completed a significant financing to support these clinical and discovery programs.

Total raised

$75M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2023